BioStorage Technologies, Inc., a worldwide provider of long- and short-term storage of biomaterials, sample management and cold chain logistics, will expand its European operations with the opening of a new 16,140 square foot (1,499 sq meters) full-service biorepository in Frankfurt, Germany.
BioStorage Technologies' expanded European operations is part of the company's strategic growth plan to accommodate a rapidly growing list of customers based in Europe. The new facility will offer worldwide, industry-compliant logistics, supply chain management and will meet all international customs and transportation regulations as well as documentation requirements. The company will begin offering services effective immediately.
"We are pleased to see such rapid global growth since opening our initial Germany-based facility in 2007," said F. John Mills, M.D., Ph.D., chief executive officer and chairman of the board at BioStorage Technologies. "Frankfurt has been an ideal location for us to create additional alliances and partnerships with companies conducting pharmaceutical research and development in Europe."
The expansion comes on the heels of BioStorage Technologies' announcement that it will create 125 new jobs in the United States by expanding its global headquarters in Indianapolis to include an additional 40,000 square foot cold-storage facility.
"Our strategic, centralized locations next to two of the largest freight hubs in the world give us the unique capability to ship critical, temperature-sensitive biomaterials and clinical trial supplies to any of our customer's locations worldwide with exceptional expediency," adds Mills.
Dr. Wolfgang Hoffer, managing director of BioStorage Technologies' European operations asserts, "The extension of our services in Europe will reinforce the scope and depth of significant biomedical and pharmaceutical research conducted by our clients in this part of the world," said Hoffer.
BioStorage Technologies' newest biorepository will continue to serve pharmaceutical and biotech firms, donor organizations and banks as well as research and academic organizations based in Europe. The new facility will feature the same unparalleled sample management services, assets and standard operating procedures currently offered at all the company's facilities.
Antibiotic activity altered by interaction with nanoplastics, new research shows